1.
Evid. actual. práct. ambul
;
20(2): 41-41, 2017. tab
Article
in Spanish
| LILACS
| ID: biblio-1128707
Subject(s)
Humans , Male , Female , Middle Aged , Aged , Quinolones/therapeutic use , Pulmonary Disease, Chronic Obstructive/drug therapy , Adrenergic beta-2 Receptor Agonists/therapeutic use , Fluticasone-Salmeterol Drug Combination/therapeutic use , Glucocorticoids/therapeutic use , Glycopyrrolate/therapeutic use , Indans/therapeutic use , Administration, Inhalation , Randomized Controlled Trials as Topic , Quinolones/adverse effects , Muscarinic Antagonists/therapeutic use , Pulmonary Disease, Chronic Obstructive/mortality , Drug Combinations , Fluticasone-Salmeterol Drug Combination/adverse effects , Glycopyrrolate/adverse effects , Indans/adverse effects
2.
Indian J Exp Biol
;
1992 Jul; 30(7): 583-6
Article
in English
| IMSEAR
| ID: sea-56077
ABSTRACT
In line of the effort towards development of some newer indanyl non-steroidal anti-inflammatory agents and providing comprehensive SAR among this class of compounds some significantly active derivatives with low ulcerogenic potential were identified. Dealing with various long chain and branched chain compounds among this series, 3-(5, 6-dimethoxy indan-1-yl) propionic acid, 2-(5, 6-dimethoxy indan-1-yl) propionic acid and 3-(6-methoxy indan-1-yl) propionic acid were observed to have encouraging biological activity. Screening in various animal models of inflammation suggests their longer duration of action and lower ulcerogenic liability.